CA2253913A1 - Sel de bismuth de sialyloligosaccharide et procede pour traiter et inhiber les ulceres gastriques et duodenaux avec cette substance - Google Patents
Sel de bismuth de sialyloligosaccharide et procede pour traiter et inhiber les ulceres gastriques et duodenaux avec cette substance Download PDFInfo
- Publication number
- CA2253913A1 CA2253913A1 CA002253913A CA2253913A CA2253913A1 CA 2253913 A1 CA2253913 A1 CA 2253913A1 CA 002253913 A CA002253913 A CA 002253913A CA 2253913 A CA2253913 A CA 2253913A CA 2253913 A1 CA2253913 A1 CA 2253913A1
- Authority
- CA
- Canada
- Prior art keywords
- oligosaccharide
- galactose
- group
- stomach
- bismuth salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Procédé pour traiter et/ou inhiber les ulcères gastriques et duodénaux, comprenant l'administration d'une composition pharmaceutique contenant un sel de bismuth d'un oligosaccharide défini par la formule (I): (NeuAc-$(a)(2-3)-pGal-.beta.(1)-(-X-)¿m?-(-Y-)¿n?-)¿p?-Z dans laquelle X = une laison chimique ou un groupe capable de lier la p galactose soit au groupe de liaison Y soit au support multivalent Z; dans laquelle l'oxygène glycosidique C¿1? de galactose peut être remplacé par N, S ou C; Y = un groupe de liaison; Z = un support multivalent; m = 0 ou 1; n = 0 ou 1; et p = un nombre entier de 2-1000. L'invention propose également un procédé pour traiter et/ou inhiber les ulcères gastriques et duodénaux par l'administration d'une composition pharmaceutique comprenant un sel de bismuth d'un oligosaccharide défini par la formule (III) (NeuAc-.alpha.(2-3)-pGal-.beta.(1)-A dans laquelle A = un groupe capable de se lier avec la p galactose et dans laquelle l'oxygène glycosidique C¿1? de galactose peut être remplacé par N, S ou C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1676596P | 1996-05-03 | 1996-05-03 | |
US60/016,765 | 1996-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2253913A1 true CA2253913A1 (fr) | 1997-11-13 |
Family
ID=21778853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002253913A Abandoned CA2253913A1 (fr) | 1996-05-03 | 1997-04-28 | Sel de bismuth de sialyloligosaccharide et procede pour traiter et inhiber les ulceres gastriques et duodenaux avec cette substance |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0918526A1 (fr) |
JP (1) | JP2000509714A (fr) |
KR (1) | KR20000010732A (fr) |
AU (1) | AU710576B2 (fr) |
CA (1) | CA2253913A1 (fr) |
WO (1) | WO1997041875A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20011403A (fi) * | 2001-06-29 | 2002-12-30 | Carbion Oy | Menetelmä ja koostumukset vatsan sairauksien hoitoon |
DE60232077D1 (de) * | 2001-06-29 | 2009-06-04 | Glykos Finland Oy | Verwendung mindestens einer glycoinhibitor-substanz gegen infektionskrankheiten |
JP5014018B2 (ja) * | 2006-10-18 | 2012-08-29 | 旭化成ケミカルズ株式会社 | ピロリ菌の抑制剤または静菌剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935406A (en) * | 1988-09-20 | 1990-06-19 | Marion Laboratories, Inc. | Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders |
MX9304638A (es) * | 1992-07-31 | 1994-05-31 | Neose Pharm Inc | Composicion para tratar e inhibir las ulceras gastricas y duodenales. |
WO1994003184A1 (fr) * | 1992-07-31 | 1994-02-17 | Neose Pharmaceuticals, Inc. | Compositions destinees a traiter et inhiber les ulceres gastriques et duodenaux |
WO1995023605A1 (fr) * | 1994-03-02 | 1995-09-08 | Neose Pharmaceuticals, Inc. | Procede de traitement et d'inhibition des ulceres gastriques et duodenaux |
-
1997
- 1997-04-28 WO PCT/US1997/006376 patent/WO1997041875A1/fr not_active Application Discontinuation
- 1997-04-28 AU AU27326/97A patent/AU710576B2/en not_active Ceased
- 1997-04-28 CA CA002253913A patent/CA2253913A1/fr not_active Abandoned
- 1997-04-28 JP JP9539929A patent/JP2000509714A/ja active Pending
- 1997-04-28 KR KR1019980708842A patent/KR20000010732A/ko not_active Application Discontinuation
- 1997-04-28 EP EP97921225A patent/EP0918526A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1997041875A1 (fr) | 1997-11-13 |
JP2000509714A (ja) | 2000-08-02 |
EP0918526A1 (fr) | 1999-06-02 |
AU710576B2 (en) | 1999-09-23 |
AU2732697A (en) | 1997-11-26 |
KR20000010732A (ko) | 2000-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5883079A (en) | Method for inhibiting H. pylori infection in mammalian tissue | |
Vishwanath et al. | Tracheobronchial mucin receptor for Pseudomonas aeruginosa: predominance of amino sugars in binding sites | |
KR19990022658A (ko) | 올리고사카라이드 화합물에 의한 박테리아 저해물질 | |
MXPA96003403A (en) | Treatment of diarrhea associated with antibioti | |
WO1994003184A1 (fr) | Compositions destinees a traiter et inhiber les ulceres gastriques et duodenaux | |
RU2306140C2 (ru) | НОВЫЕ РЕЦЕПТОРЫ ДЛЯ Helicobacter pylori И ИХ ПРИМЕНЕНИЕ | |
AU709149B2 (en) | Method for treating and inhibiting gastric and duodenal ulcers | |
JP2006511497A (ja) | ヘリコバクターピロリに対する高親和性レセプターおよびその用途 | |
CN100338085C (zh) | 唾液酸化的碳水化合物 | |
AU710576B2 (en) | Bismuth salt of sialyloligosaccharide and a method for treating and inhibiting gastric and duodenal ulcers with same | |
US20050220819A1 (en) | Novel binding epitopes for helicobacter pylori and use thereof | |
WO1998026662A1 (fr) | Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales | |
JP2010532388A (ja) | ポリシアル酸脱n−アセチラーゼの阻害剤及びその使用方法 | |
MXPA98009158A (en) | Salt of bismuto de sialiloligosacarido and a metodopara treat and inhibit gastric and duodenal ulceras with the mi | |
JP2003535965A5 (fr) | ||
JP2003535965A (ja) | インフルエンザウイルス結合性シアル化オリゴ糖含有物質およびその用途 | |
EP1169044A1 (fr) | Structures glucidiques de n-acetyl lactosamine fucosyle sialyle permettant d'inhiber l'adhesion bacterienne | |
JPH1045602A (ja) | ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−8産生阻害剤 | |
WO2004065400A1 (fr) | Nouveaux epitopes de liaison a helicobacter pylori et utilisation desdits epitopes | |
US20020173483A1 (en) | Chlamydia oligosaccharides | |
KR20010022739A (ko) | 헬리코박터 필로리의 정착 저해제 | |
Simon | Section Review: Biologicals & Immunologicals: Complex carbohydrates in development as human pharmaceuticals | |
JP2004002239A (ja) | TNF−α産生抑制剤 | |
HISANO et al. | Influence of Macrolide Antibiotics on Co-stimulatory Molecule Expression on Mouse Splenic B-lymphocytes in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |